Cemiplimab + Chemotherapy Aids Quality of Life With Lung Cancer
WEDNESDAY, May 10, 2023 (HealthDay News) -- Cemiplimab plus chemotherapy results in significant overall improvement in pain symptoms and delayed deterioration in cancer-related and lung cancer-specific symptoms and functions, according to a study published online May 8 in Cancer.
Tamta Makharadze, M.D., from LTD High Technology Hospital Med Center in Batumi, Georgia, and colleagues evaluated patient-reported outcomes from the EMPOWER-Lung 3 phase 3 trial. The analysis included 312 patients assigned to cemiplimab plus platinum-doublet chemotherapy and 154 receiving placebo plus chemotherapy as first-line treatment for advanced non-small cell lung cancer.
The researchers found that for pain symptoms, there was a statistically significant overall improvement from baseline and significant delay in time to definitive clinically meaningful deterioration (TTD; hazard ratio, 0.39; 95 percent confidence interval, 0.26 to 0.60; P < 0.0001) favoring cemiplimab plus chemotherapy. For functioning and symptom scales, there were also statistically significant delays seen in TTD, all favoring cemiplimab plus chemotherapy. From baseline, there was a significant overall improvement observed in global health status/quality of life with cemiplimab plus chemotherapy versus a nonsignificant overall change from baseline for placebo plus chemotherapy (hazard ratios [95 percent confidence intervals], 1.69 [0.20 to 3.19] versus 1.08 [−1.34 to 3.51]; between arms, P = 0.673).
"We show that the favorable efficacy achieved with cemiplimab plus chemotherapy over placebo plus chemotherapy is accompanied by significant overall improvement in pain and significant delay in TTD in multiple patient-reported cancer-related and lung cancer-specific functions and symptoms," the authors write.
Several authors disclosed financial ties to Regeneron, which manufactures cemiplimab and funded the study.
Related Posts
El aire contaminado significa más ataques de asma para los niños urbanos
VIERNES, 6 de enero de 2023 (HealthDay News) -- La contaminación atmosférica...
‘Neuroprotectant’ Drug Could Boost Outcomes After a Stroke
THURSDAY, Feb. 9, 2023 (HealthDay News) -- Using a "neuroprotectant" drug...
In Michigan Poll, 1 in 5 Adults Say They Don’t Want Kids
MONDAY, April 10, 2023 (HealthDay News) -- Not everyone wants children, and that...
La ivermectina y Luvox fracasan como tratamientos para la COVID-19
JUEVES, 18 de agosto de 2022 (HealthDay News) -- Dos medicamentos que se...